Table 1.

Participant characteristics. Data recorded within ± 6 months of the index date. Data are means (SD) unless otherwise noted.

CharacteristicsConcurrent, n = 102Biologic Alone, n = 206
Missing Data, n (%)Missing Data, n (%)
Women, n (%)90 (88.2)0 (0)158 (76.7)0 (0)
Age, yrs66.4 (10.6)0 (0)57.3 (11.7)2 (1.0)
Followup time from index date, yrs2.4 (1.2)0 (0)2.5 (1.3)0 (0)
Duration on denosumab, yrs2.4 (1.2)0 (0)NANA
Body mass index, kg/m227.3 (5.5)2 (2.0)31.2 (6.3)38 (18.4)
BMD T score ≤ −2.5 at the spine or hip, n (%)45 (46.9)6 (5.9)23 (13.4)34 (16.5)
History of fracture, n (%)8 (8.3)6 (5.9)4 (2.5)44 (21.4)
Cardiovascular disease, n (%)7 (6.9)0 (0)19 (9.2)0 (0)
Chronic kidney disease, n (%)1 (1.0)0 (0)4 (1.9)0 (0)
Chronic obstructive pulmonary disease, n (%)4 (3.9)0 (0)16 (7.8)0 (0)
Diabetes, n (%)8 (7.8)0 (0)25 (12.1)0 (0)
Liver disease, n (%)1 (1.0)0 (0)1 (0.5)0 (0)
Smoking status, n (%)113
  Past25 (24.8)NA52 (26.9)NA
  Current12 (11.9)NA37 (19.2)NA
  Never64 (63.4)NA104 (53.9)NA
Baseline rheumatoid arthritis disease activity
  C-reactive protein, mg/l4.6 (6.8)23 (22.5)4.5 (8.0)38 (18.4)
  ESR, mm/h19.0 (17.0)24 (24.5)17.2 (15.2)38 (18.4)
  Swollen joint count4.7 (4.2)37 (36.3)4.8 (5.0)38 (18.4)
  Tender joint count8.2 (10.1)44 (43.1)6.6 (7.0)45 (21.8)
  • Summary statistics and percentages are calculated based on non-missing observations. Percentages for missing data are calculated based on total population for each group (n = 102, concurrent group; n = 206, biologic-alone group). BMD: bone mineral density; NA: not applicable; ESR: erythrocyte sedimentation rate.